UCB (OTCMKTS:UCBJF) Reaches New 12-Month High - Time to Buy?

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $232.48 and last traded at $232.48, with a volume of 7955 shares. The stock had previously closed at $227.63.

Analysts Set New Price Targets

Separately, Morgan Stanley raised shares of UCB to an "overweight" rating in a research note on Monday, June 23rd. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy".

UCB Trading Up 0.7%

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The stock's 50-day simple moving average is $209.53 and its 200 day simple moving average is $187.90.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.